Study S002169

An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT00516048
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 58
Start: 2007-08
Primary completion: 2008-04
Lead sponsor: AstraZeneca
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:exenatide
Results posted: TRUE

Registered primary outcomes

Treatment-emergent Antibody Status (Maximum Titer Level Experienced) [24 weeks]
Incidence of Potentially Immune-related Treatment-emergent Adverse Events [24 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.